







Fig S4









D

















1 2

4

#### Supplementary Information (SI) Appendix

#### 3 SUPPLEMENTARY FIGURE LEGENDS

## Supplementary Fig 1: Relative levels of LD formation proteins following FA treatment as well as analysis of FIT2 in islets of βFIT2KO mice.

7 **A-D**, Semi-guantitation of immunoblots for FIT2, Seipin, Perilipin2 and CHOP protein 8 levels in MIN6 cells treated with palmitoleate (16:1), oleate (18:1), palmitate (16:0), stearate (18:0) (300 µM, 24 h) or BSA control (N=3). E, Representative in situ 9 10 hybridization image for FIT2 mRNA (red) combined with immunohistochemistry for 11 insulin (green) in pancreatic cryosections from C57BL/6 mice. DAPI was used to 12 counterstain the cell nucleus (blue). Expanded image (right) of the demarcated 13 section. Images shown are maximum-intensity projections. Scale bar = 50  $\mu$ m. F, 14 Semi-quantitation of immunoblot analysis of FIT2 expression in vector only (Ctrl 15 shRNA) or stable FIT2 knockdown (FIT2 shRNA) MIN6 cells treated with or without palmitate (300 µM, 24 h). G, Representative immunoblot and H, corresponding semi-16 17 quantitation of FIT2 protein in isolated islets from floxed control (FL) and βFIT2KO 18 (KO) mice (12 wk-old male, N=7). I, Gene expression (qPCR) analysis of FIT2 19 mRNA levels in pancreatic islets, adipose tissue, liver and hypothalamus of floxed 20 control (FL) and βFIT2KO (KO) mice (12 wk-old male, N=3-4). J, Body weight of 21 floxed control (FL) and βFIT2KO (KO) fed with chow diet (FL Chow, KO Chow) or 22 West diet (FL West, KO West) for 25 weeks (30 wk-old at time of analysis, male, N=6). Values shown are mean ± SEM; \*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001 23 24 relative to control (A, B, C, D: one-way ANOVA with Tukey's post-hoc test, F, J: two-25 way ANOVA with Šidák post-hoc test), H, I: two-tailed Student's T-test.

#### 26

#### 27 Supplementary Fig 2: Islet characteristics of βFIT2KO mice.

28 **A**, Representative immunostaining for insulin (red), glucagon (green) and somatostatin (white) in pancreas sections from FL and KO mice (12 wk-old male). 29 30 Scale bar = 50  $\mu$ m. **B**, **C**, Cell-type distribution and  $\beta$ -cell size analysis of *in situ* islets 31 in pancreas sections from floxed control (FL) and BFIT2KO (KO) mice (12 wk-old 32 male, N=4-5). D, E, Measurements of total pancreas (N=4) and islet (N=7) insulin content. F, Representative Transmission Electron Microscope (TEM) images of 33 34 insulin granules of FL and KO pancreata (N=3). Scale bar = 1  $\mu$ m. **G**, ATP/ADP ratio 35 of FL and KO islets in 2.8 mM glucose (2.8 G) followed by stimulation with 16.7 mM 36 glucose (16.7 G). (N=4). H, Measurements of changes in [Ca<sup>2+</sup>], in FL and KO islets 37 exposed to varying concentrations of glucose "G" as indicated (15-20 islets from four 38 independent experiments were analyzed per group). I, AUC of [Ca<sup>2+</sup>]; at 16.7 mM 39 glucose (N=15-20). J, AUC of [Ca<sup>2+</sup>] at 25 mM KCl (N=15-20). L, K, Measurements of capacitance change in FL and KO islets. L, Representative traces of capacitance 40 41 recording obtained with a train of 10 consecutive depolarising pulses (500 ms steps, 100 ms interval) from -70 mV to 0 mV on FL (blue) and KO (red) islets. K, 42 43 Quantification of changes in capacitance upon the 10th depolarising pulse induction 44 between FL and KO islets (N=12 islets from 3 different 12-wk old mice each). M, 45 gPCR validation of RNA-Seq results with respect to changes seen in key β-cell genes (N=5). Values shown are mean ± SEM; \*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001 46 47 (B, C, D, E, I, J, L, M: two-tailed Student's T-test, G: two-way ANOVA with Šidák 48 post-hoc test).

49

#### 50 Supplementary Fig 3: Relative levels of ER stress proteins and ceramide 51 immunodetection in pancreas of βFIT2KO mice.

A-D, Semi-quantitation of immunoblot analysis of IRE1a, p-IRE1a, ATF4 and CHOP 52 53 protein levels in scrambled (Ctrl shRNA) or FIT2 knockdown (FIT2 shRNA) MIN6 54 cells in the absence (BSA) or presence of palmitate (300 µM, 24 h). E, Ex vivo 55 insulin secretion, represented as Stimulation Index (16.7 mM / 2.8 mM), from 56 scrambled (Ctrl shRNA) or FIT2 knockdown (FIT2 shRNA) MIN6 cells. F, 57 Representative immunostaining image for insulin (red), ceramide (green) and DAPI 58 (blue) in pancreas sections from western diet fed FL and KO mice (30 wk-old, male, 59 N=3). Scale bar = 50 µm. G, Quantitation of ceramide fluorescence intensities from 60 floxed control (FL) and BFIT2KO (KO) islets of western diet fed mice (30 wk-old, 61 male, N=3) (normalised to FL) using Image-J. Values shown are mean ± SEM; \*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001 (A, B, C, D: two-way ANOVA with Šidák post-hoc 62 test. E. G: two-tailed Student's T-test. 63

64

# Supplementary Fig 4: Relative changes in gene and protein levels of FIT2 following exposure to different FAs and separately on MARCH6 and AMFR knockdown in MIN6 cells.

A, Relative FIT2 mRNA levels (gPCR) in MIN6 cells treated with BSA or different 68 FAs (300 µM) for 24 h (N=3). B-E, MIN6 cells were transiently transfected with a 69 70 scrambled (ctrl siRNA) or different siRNA oligonucleotides targeting either March6 or 71 Amfr. 48 h after transfection, cells were serum-starved for 2 h followed by treatment 72 with either BSA or palmitate (300 µM) for 4 h. **B**, Relative *March6* gene expression 73 levels following siRNA mediated knockdown. C, D, Changes in FIT2 protein following 74 AMFR knockdown and palmitate (300 µM, 4h) exposure. E, Relative Amfr gene 75 expression levels following siRNA mediated knockdown. F, Schematic 76 representation of point mutants (C  $\rightarrow$  A) of FIT2. **G**, **H**, Click-iT palmitoylation assay 77 of FIT2 protein in MIN6 cells transiently transfected with pcDNA3.1-FIT2/V5-His and 78 pre-treated with 10 µM MG132 for 2 h followed by DMSO (Vehicle control) or 200 µM Click-IT<sup>™</sup> Palmitic Acid. Azide treatment for 6 h. I, J, Representative immunoblot 79 80 analysis and semi-quantification of FIT2 protein levels in MIN6 cells transfected with 81 pcDNA3.1-FIT2/V5-His (WT) or mutants followed by treatment with BSA or palmitate 82 (300 µM, 24 h). K, treatment of wild-type or guadruple mutant FIT2 with stearate 83 (300 µM) for 24 h (N=3-4). Values shown are mean ± SEM; \*, P < 0.05; \*\*, P < 0.01; 84 \*\*\*, P < 0.001 (A, J: one-way ANOVA with Tukey's post-hoc test, B, D, E, H, L: two-85 tailed Student's T-test.

86

#### 87 SUPPLEMENTARY MATERIALS AND METHODS

88

#### 89 Islet isolation, dispersion and cell culture

90 Mouse pancreatic islets were isolated by perfusing the pancreas through the 91 common bile duct with collagenase. The isolated islets were dispersed into single 92 cells by incubation with Accutase at 37°C for 3-5 min. The primary islet cells were 93 cultured in CMRL medium supplemented with 10% heat-inactivated fetal bovine 94 serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. The mouse pancreatic β-cell line MIN6 was kindly provided by Dr. Jun-ichi Miyazaki, Osaka University, 95 96 Japan (1). MIN6 cells (passages 30-35) were cultured in DMEM containing 25 mM 97 glucose,10% heat-inactivated fetal bovine serum, 4 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 50 µM 2-mercaptoethanol. HEK 293T/17 cells 98 99 were cultured in Dulbecco's modified Eagles medium (DMEM, 25 mM glucose) 100 containing 10% fetal bovine serum, 4 mM L-glutamine, 100 U/ml penicillin and 101 100 µg/ml streptomycin. Cells were maintained at 37 °C under 5% CO2 and 95% air 102 condition. Transient transfections of Min6 and HEK 293T/17 cells were performed 103 using Liofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's 104 instructions. FFAs (palmitate, stearate, oleate and linoleate) were conjugated with 105 FFA-free BSA at a 2:1 molar ratio and used at a final concentration of 300 µM.

106

107 Lentiviral transduction for generation of shRNA-mediated stable knockdown cell

108 lines.

109 MISSION lentiviral transduction particles expressing shRNA targeting FIT2 110 (SHCLNV-NM 173397) and lentiviral-negative control particles (SHC002V) were 111 purchased from Sigma-Aldrich. Stable transduced cell lines were generated 112 according to the manufacturer's instructions. Briefly, cells were seeded on a 12-well 113 plate and infected with the lentiviral particles the following day. After 24 h medium 114 was changed. Selection of lentiviral expressing cells started 24 h later with the 115 addition of 2 µg/ml puromycin. Knockdown efficiency of different cell lines was 116 determined by immunoblotting and real-time PCR.

- 117
- 118 Protein extraction and immunoblotting assays
- 119 Cells and isolated islets were lysed in RIPA buffer supplemented with protease 120 inhibitor cocktail. Proteins were separated by SDS-PAGE and transferred onto 121 nitrocellulose membranes. Blocking was performed at room temperature for 1 h in 122 Tris-buffered saline (TBS) with 5% non-fat milk, followed by incubation with the 123 different primary antibodies (described below) in TBS with 5% non-fat milk for either 124 1 h at room temperature or overnight at 4 °C. After several washes with TBS 125 containing 0.5% Tween 20 (TBST), the membranes were incubated with secondary 126 antibodies of anti-mouse/rabbit IgG/HRP (as appropriate) in TBS with 1% non-fat 127 milk. Following several washes, the protein bands were visualized using enhanced 128 chemiluminescence (Cell Signaling Technology) and guantified using ImageJ.
- 129

#### 130 RNA extraction and quantitative RT-PCR

Total RNA was prepared from tissues or cells using NucleoSpin RNA II kit 131 132 (Macherey-Nagel), or prepared from the isolated islets using the RNeasy® Plus Mini 133 Kit (Qiagen). 1 µg of RNA was reversely transcribed using High Capacity cDNA 134 Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's 135 instructions. Real-time PCR was performed on QuantStudio 6 Flex Real-Time PCR 136 System (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied

- 137 Biosystems). The PCR primers used are summarized in Supplementary Table 3.
- 138
- 139 RNA-seq library preparation

Pancreatic islets were isolated from 12 week old wild type (WT) and  $\beta$ -cell specific 140 141 FIT2 knockout (β-FIT2KO, KO) mice in quintuplicate. Isolated pancreatic islets then 142 cultured in complete CMRL medium overnight for recovery. Total RNA was 143 harvested using RNeasy Plus Mini Kit (Qiagen). RNA-seg library construction was 144 conducted by Segmatic. Briefly, polyA-tail specific mRNA libraries were prepared 145 from 1 ug of total RNA with Illumina TruSeg stranded mRNA library preparation 146 protocol followed by single-end 75bp sequencing with the Illumina NextSeq to 147 generate an average of 50,578,630 reads per sample.

148

#### 149 RNA-Seq data processing

150 Sequenced reads were aligned to the mm10 (GRCm38) mouse genome with STAR 151 version 2.5.2a (2) and transcripts were assembled with RSEM version 1.3.0 (3). 152 Cuffnorm version 2.2.1 (4, 5) was used to obtain guartile-normalized fragments per 153 kilobase per million reads (FPKM) expression matrix of genes across all samples. 154 Cuffdiff2 version 2.2.1 (4, 5) was used to identify differential genes between 155 samples. Genes were considered to be significantly differentially expressed when 156 false discovery rate (FDR)  $\leq$  0.05, with FPKM  $\geq$  1 in one sample group retained for 157 subsequent analysis. GO clustering enrichment analysis was carried out on 158 differential genes using the Functional Annotation tool in DAVID version 6.8 under 159 medium stringency for all default annotation categories except protein domains. We 160 identified significant clustered groups having group enrichment scores of  $\geq$  1.3, with 161 higher scores indicative of more significant annotated GO clusters. Heatmaps were 1.0.10 162 generated with R package pheatmap version (https://cran.r-163 project.org/web/packages/pheatmap/index.html).

164

#### 165 <u>Immunofluorescence</u>

166 Pancreata were fixed with 4% paraformaldehyde for 6 h, followed by incubation with 30% sucrose overnight at 4 °C. Cryosections of 10 µm thickness were used for 167 immunofluorescence analysis. Sections were rinsed with TBS, permeabilized, and 168 blocked with 10% normal goat serum plus 0.2% Triton X-100 in TBS for 1 h at room 169 170 temperature and then incubated overnight with primary antibodies at 4°C in a 171 humidified atmosphere. After gentle washing with TBS and incubating with 172 fluorescence secondary antibodies for 1 h at room temperature, sections were 173 mounted with Vecta Mount solution (Vector Labs) and analysed by confocal imaging 174 (Leica). For LD staining, cryosections were stained with BODIPY 493/503 (0.01mg/ml) and DAPI (5 µg/ml) for 15 min at RT. For propidium iodide (PI) staining, 175 176 cells were incubated with 10 µg/ml PI and 5 µg/ml DAPI in medium for 1h at 37 °C 177 followed by RT fixation. Images were captured using a SP8 confocal microscope 178 (Leica). BODIPY-positive puncta per cell and percentage of PI-positive cells were 179 quantified using Image-J and Prism 7 (GraphPad).

- 180
- 181 LD staining

182 Cells were fixed with 4% paraformaldehyde solution for 15 min at RT. Fixed cells or 183 pancreas cryosections of 10  $\mu$ m thickness were stained with BODIPY 493/503 184 (0.01mg/ml) and DAPI (5  $\mu$ g/ml) for 15 min at RT. Images were captured using a 185 SP8 confocal microscope (Leica). BODIPY-positive puncta per cell was gauntified

186 using Image-J and Prism 7 (GraphPad).

187

#### 188 Propidium Iodide staining

189 Cells were incubated with 10  $\mu$ g/ml propidium iodide (PI) and 5  $\mu$ g/ml DAPI in 190 medium for 1h at 37 °C. After 3 times washing with phosphate-buffered saline (PBS), 191 cells were fixed with 4% paraformaldehyde solution for 15 min at RT and subjected 192 to confocal imaging. Percentage of PI-positive cells was quantified using Image-J 193 Prism 7 (GraphPad).

194

#### 195 Islet cell composition and beta β-cell size

196 Islet cell composition was determined by dividing the number of individual cell types 197 ( $\alpha$ ,  $\beta$  or  $\delta$  cells) by the total islet cell number per islet.  $\beta$ -cell size was determined by 198 dividing the insulin-positive area of each islet by the number of insulin-positive cells 199 within the same islet. For each group, >40 islets from non-serial sections of 200 pancreatic tissues from 5 animals were analyzed for both  $\beta$ -cell size and islet cell 201 composition.

202

#### 203 <u>Transmission electron microscopy</u>

Mouse pancreas were either directly fixed at room temperature using 4% 204 205 formaldehyde/2% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) in 0.1 206 M sodium cacodylate, pH 7.4, or cryo-fixed overnight as described previously (47). 207 Tissue samples were then washed twice with 0.1 M cacodylate buffer, post-fixed for 208 2 h in a mixture consisting of 1% osmium tetroxide (EMS) and 1.5% potassium 209 ferrocyanide (EMS) in 0.1M cacodylate, pH 7.4. Post-fixed tissues were washed with 210 distilled H2O and dehydrated through an ethanol series (25%, 50%, 75%, 85%, 90%, 211 95%, 100%) and then in propylene oxide (EMS). Samples were subsequently embedded in Epoxy resin for 1 h at 42 °C followed by 48 h at 65 °C. For all samples, 212 213 ultrathin sections of 50 nm were cut with diamond knife (Diatome, Switzerland) on 214 Leica Ultracut EM UC7 ultramicrotome (Leica Microsystems, Germany) and 215 collected onto formvar/carbon copper slot grids (EMS). Sections on grids were 216 contrasted with 4% aqueous uranyl acetate followed by Reynold's lead citrate and 217 analysed with a JEM-1010 Jeol transmission electron microscope (JEOL Ltd., 218 Japan) operating at 80 kV. Images were acquired with SIA model 12C high 219 resolution full-frame CCD camera.

220

### 221 <u>Total islet and pancreatic insulin content</u>

To determine islet insulin content, around 10 isolated islets were washed twice with 222 223 ice-cold D-PBS and then lysed with RIPA buffer. Insulin and protein content of the 224 lysate were measured using Mercodia Mouse Insulin ELISA (Mercodia) and BCA 225 assay (Thermo Fisher Scientific), respectively. Total islet insulin content was 226 normalized to total protein content. To determine pancreatic insulin content, half of 227 the whole pancreas was collected and placed into 5 ml Acid-Ethanol solution (1.5% 228 HCl in 70% EtOH) overnight at -20°C. Tissue was then homogenized and incubated 229 in the same solution overnight at  $-20^{\circ}$ C. Supernatant was collected by centrifugation 230 at 3000 x g for 10 min at 4°C, followed by neutralization with 1 M Tris pH 7.5 at 1:1 (vol/vol). Insulin and protein content of the neutralized solution were measured. Total 231 232 pancreatic insulin content was normalized by total protein content.

233

#### 234 Glucose Stimulated Insulin Secretion (GSIS) Assay

235To measure GSIS in Min6 cells, cells were pre-incubated at 37°C for 2 hr in KRBH236buffer (119 mM NaCl, 4.74 mM KCl, 2.54 mM CaCl2, 1.19 mM MgCl2, 1.19 mM

KH2PO4, 25 mM NaHCO3, and 10 mM HEPES, pH 7.4) containing 0.1% BSA and
0.1 mM glucose. After washing with the same buffer, cells were then incubated in the
KRBH buffer containing 0.1% BSA and 0.1 mM glucose at 37°C for 30 min, followed
by incubation with KRBH buffer containing 0.1% BSA and 25 mM glucose for
another 30 min. The supernatant was collected for insulin measurements.

242 To measure GSIS in the isolated islets, islets were pre-incubated at 37°C for 2 hr in buffer containing 125 mM NaCl, 5.9 mM KCl, 2.56 mM CaCl2, 1.2 mM MqCl2, 25 243 mM HEPES, 0.1% BSA and 2.8 mM glucose, pH 7.4 (2.8 G buffer). Batches of 244 245 around 50 islets were placed between two layers of bio-gel (Bio-Rad) in a perifusion 246 chamber and perifused at a flow rate of 200 µL/min, at 37°C, with 2.8 G buffer for 20 247 min prior to the start of collecting samples. To determine the dynamic response of 248 insulin secretion, islets were first perifused for 10 min with 2.8 G buffer, followed by 249 10 min with buffer containing 125 mM NaCl, 5.9 mM KCl, 2.56 mM CaCl2, 1.2 mM 250 MgCl2, 25 mM HEPES, 0.1% BSA and 16.7 mM glucose, pH 7.4 (16.7 G buffer), 251 prior to incubation with 2.8 G buffer for 30 min. Samples were collected every 2 min 252 for insulin measurements. At the end of the perifusion assay, islets were lysed in RIPA buffer and total insulin content was measured. GSIS was normalized by total 253 254 islet insulin content.

To measure GSIS *in vivo*, mice were starved for 6 hr and blood were collected from tail vein to determine basal insulin levels. Mice were then injected with 2 g glucose/kg of body weight, intraperitoneally. Blood samples were collected from the tail vein 15 min after glucose injection. Total blood was centrifuged at 10,000 *x g* for 10 min and the supernatant (serum) was collected for insulin measurements using Mercodia Mouse Insulin ELISA (Mercodia).

261

#### 262 Insulin and glucose tolerance tests

Prior to GTT or ITT, mice were fasted for 6 h with ad libitum access to water and then administered glucose (2 g/kg) or insulin (0.75 unit/kg) intraperitoneally. Blood glucose was measured in blood samples collected from tail vein using a glucometer (Accu-Chek Performa Nano System).

267

#### 268 In vitro [Ca<sup>2+</sup>], imaging and data analysis

269 In vitro imaging of whole intact islets was carried out 1-2 days after isolation from FL 270 and KO animals. Changes in cytosolic free Ca2+ concentration were measured 271 using fura2-AM on a fluorescence wide-field microscope (Leica DMI6000B). Single 272 islets were attached to glass coverslips using a peptide hydrogel (Corning Inc., 273 354250) inside an open recording chamber (Warner Instruments), with the whole 274 system maintained at 37°C. Prior to imaging, islets were starved for 1 h in 2.8 G 275 buffer containing 4 uM Fura2-AM. Islets were stimulated with a glucose concentration of 16.7 mM, Fura-2 fluorescence was measured using the excitation 276 277 from a xenon lamp (Sutter DG-4) and fura-2 filter set (Excitation 340/380 nm; 278 Dichroic 415 nm; Emission 510 nm). Responses were measured as area under the 279 curve (AUC), computed using the trapezoidal method. Due to the lack of a clear 280 peak and drifting baseline for the FIT2 KO group, the AUC was measured for only the first 120 s of the response to high glucose. Analysis was carried out using 281 282 ImageJ and Prism 7 (GraphPad).

283

#### 284 ATP/ADP Ratio

FL or KO islets were pre-incubated in 2.8 G buffer for 2 hr, then incubated with a 2.8 G or a 16.7 G buffer for 15 min. ATP/ADP ratio was determined with ADP/ATP Ratio

- Bioluminescence Assay Kit (Biovision), according to manufacturer's instruction.
- 288

#### 289 <u>Membrane Capacitance</u>

290 Membrane capacitance were recorded from intact pancreatic islets using the 291 standard whole cell patch clamp technique and software lock-in module of the 292 Patchmaster software together with an EPC10/2 amplifier (HEKA Elektronik). An 800 293 Hz, 25 mV peak-to-peak sinusoidal wave was applied around a holding potential of -294 70 mV. β-cell exocytosis was triggered with 10 consecutive 500 ms depolarization 295 pulses (-70 to 0 mV) with 100 ms intervals. β -Cells were identified based on their 296 size (Cm > 5 pF) and discernible voltage-gated Na+ currents (6). Islets are bathed in 297 extracellular solution containing the following: 118 mmol/L NaCl, 5.6 mmol/L KCl, 1.2 298 mmol/L MgCl2, 10 mmol/L CaCl2, 20 mmol/L tetraethylammonium chloride, 5 299 mmol/L HEPES, and 5 mmol/L glucose (310 mOsm, pH 7.4). The bath was perfused 300 continuously, and all recordings were carried out at room temperature. Recording 301 pipettes were pulled with P-1000 (4-7 MΩ; Sutter Instrument Co.) and filled with an 302 internal solution containing the following: 125 mmol/L Cs-glutamate, 10 mmol/L CsCl, 10 mmol/L NaCl, 1 mmol/L MgCl2, 5 mmol/L HEPES, 0.05 mmol/L EGTA, and 303 304 3 mmol/L MgATP (300 mOsm, pH 7.3).

305

#### 306 In situ RNA hybridization

307 In situ hybridization for FIT2 mRNA on pancreas tissue was performed using 308 RNAscope 2.5 HD Detection Kit - RED (Advanced Cell Diagnostics) according to the 309 manufacturer's instructions. Briefly, mouse pancreas was fixed with 4% PFA for 6 hr 310 at 4 °C. The fixed tissues were then immersed gradually through a series of 10%, 311 20% and 30% sucrose, frozen in the Optimal Cutting Temperature (OCT) embedding 312 media and cut at 10 µm thickness. Tissue sections were sequentially pretreated with RNAscope Hydrogen Peroxide, RNAscope Target Retrieval and RNAscope 313 314 Protease Plus regeants prior to hybridization with the target oligo probes. The 315 signals were then amplified and developed, followed by counterstaining insulin and 316 nuclei with IHC using anti-insulin antibody, Alexa 488-labeled anti-guinea pig 317 antibody and DAPI. Images were captured using the SP8 confocal microscope 318 (Leica).

319

#### 320 <u>Ceramide analysis</u>

321 Pancreatic islets were resuspended in 100 µL of butanol/methanol (1:1, v:v) spiked 322 with 66.07 nM of C8 Ceramide (d18:1/8:0) purchased from Avanti Polar Lipids 323 (860508). Cells were sonicated for 30 min followed by centrifugation at 14,000 g for 324 10 min at 22 °C. The supernatant was transferred to MS vials for analysis. The 325 samples were analysed using an Agilent 1290 series UHPLC system connected to an Agilent 6495 QQQ mass spectrometer after separation on a ZORBAX Eclipse 326 327 plus C18 column (2.1 x 50 mm, 1.8 µm, 95 Å, Agilent) at 40 °C. The injection volume 328 was 2 µL. Solvent A consisted of 60% water/40% acetonitrile (v/v) with 10mM 329 ammonium formate; solvent B consisted of 90% isopropanol/10% acetonitrile (v/v) 330 with 10mM ammonium formate. The gradient started with a flow rate of 0.4 mL/min at 20%B and increased to 60% B at 2 min, 100% B at 7 min, held at 100% B until 9 331 332 min, followed by equilibration with 20% B from 9.01 min until 10.8 min. The column 333 effluent was introduced to the Agilent 6495 QQQ mass spectrometer via AJS-ESI ion 334 source operating under the following conditions: Gas temperature, 200°C; gas flow, 335 14 L/min; nebulizer, 20 psi; sheath gas temperature, 250°C; sheath gas flow, 11 336 L/min; capillary, 3500 V. Mass spectrometry analysis was performed in positive ion

mode with dynamic scheduled multiple reaction monitoring (dMRM). Mass
spectrometry settings, LC-MS gradient and MRM transitions for each lipid class were
adapted from a previously published method (53). Data analysis was performed on
Agilent MassHunter Quantitative analysis software. Relative quantitation was based
on one-point calibration with Ceramide d18:1/8:0. The data were further normalized
to the total number of islets in each sample.

343

#### 344 <u>Co-immunoprecipitation assay</u>

345 MIN6 cells, transiently co-transfected with pcDNA3.1-FIT2/V5-His and GFP-tagged 346 MARCH6 (BC059190) Mouse Tagged ORF Clone (Origene), were pre-treated with 347 10 µM MG132 (Cell Signaling Technology) for 2 h and subsequently treated with 300 348 µM palmitate (BSA-conjugated) for 6 h. Cells were then lysed in IP lysis buffer 349 (ThermoFisher Scientific), supplemented with protease inhibitor cocktail. Co-350 immunoprecipitation assay was then performed on the protein lysates using Pierce™ 351 Classic IP Kit (ThermoFisher Scientific) with either Anti-6X His tag antibody (Abcam) 352 or Rabbit IgG (Cell Signaling Technology) in accordance with the manufacturer's 353 instructions. The eluted fraction was then subjected to immunoblotting assay and 354 MARCH6 was detected using Mouse monoclonal turboGFP antibody (Origene).

355

#### 356 <u>S-Palmitoylation Assays</u>

357 Thiol side-chain protection assay: MIN6 cells, transiently transfected with pcDNA3.1-358 FIT2/V5-His, were pre-treated with 10 µM MG132 (Cell Signaling Technology) for 2 h 359 and thereafter treated with 300 µM palmitate (BSA-conjugated) for 6 h. S-360 palmitoylation assay was then performed using CAPTUREome™ S-Palmitoylated Protein Kit (Badrilla) in accordance with manufacturer's instruction. Briefly, cell lysis 361 362 and free thiol blocking (blocking of free thiols on non-palmitoylated cysteine residue) was performed by incubating cells with the provided lysis buffer for 4 h with constant 363 shaking. Proteins were then precipitated using acetone, and subsequently 364 resuspended in the provided binding buffer. 30 µl of resuspended proteins were 365 collected as the Input Fraction (IF), while the remainder was split into two tubes: 366 "experimental" and "negative control". In the experimental tube, proteins were treated 367 368 with thioester cleavage reagent, which cleaves off acyl groups from the protein, 369 resulting in the exposure of a free thiol group. Treated samples were then subjected 370 to CAPTUREome<sup>™</sup> resin for 2.5 h at room temperature, where proteins with free 371 thiols were captured by the resin. 50 µl of flowthroughs were collected as the cleaved 372 unbound fraction (cUF). S-acylated proteins, which were captured by the 373 CAPTUREome<sup>™</sup> resin, were eluted by incubating the resin in 50 µl of 2x laemmli 374 buffer at 60°C for 10 min (cleaved Bound Fraction (cBF)). In the negative control 375 tube, proteins were treated with acyl-preservation reagent, which preserves acyl 376 groups on the protein. Treated samples were then subjected to CAPTUREome™ 377 resin for 2.5 h at room temperature. 50 µl of flowthroughs were collected as 378 preserved unbound fraction (pUF). Proteins were eluted from the CAPTUREome™ 379 resin by incubation of resin with 50 µl of 2x laemmli buffer at 60°C for 10 min 380 (preserved Bound Fraction (pBF)).

Click-chemistry S-palmitoylation Assay: MIN6 cells, transiently transfected with
pcDNA3.1-FIT2/V5-His, were pre-treated with 10 µM MG132 (Cell Signaling
Technology) for 2 h and thereafter treated with 200 µM Click-IT<sup>™</sup> Palmitic Acid,
Azide (ThermoFisher Scientific) for 6 h. Cells were then lysed in 50 mM Tris-HCL,
pH 8.0, supplemented with 1% SDS and protease inhibitor cocktail. Palmitoylated
proteins were conjugated using the Click-iT<sup>®</sup> Protein Reaction Buffer Kit

- (ThermoFisher Scientific), in accordance with manufacturer's instructions, withoutmodifications.

## 391 SUPPLEMENTARY TABLE OF REAGENTS

#### 

REAGENT or RESOURCE	SOURCE	IDENTIFIER	Lot
Antibodies			
Rabbit polyclonal anti-FIT2	Dr. David L. Silver	(7)	
Rabbit polyclonal anti-Seipin	Abcam	Cat# ab106793	
Rabbit polyclonal anti-Perilipin-2	Novus Biologicals	Cat#NB110- 40877	Lot# F-1
Rabbit polyclonal anti-CHOP (F-168)	Santa Cruz Biotechnology	Cat# sc-575	Lot# F2613
Rabbit polyclonal anti-ATF4 (C-20)	Santa Cruz Biotechnology	Cat# sc-200	Lot# G0115
Rabbit polyclonal anti-p-elF2α (Ser 52)	Santa Cruz Biotechnology	Cat# sc-101670	Lot# C0714
Rabbit monoclonal anti-IRE1α (14C10)	Cell Signaling Technology	Cat#3294	Lot# 9
Rabbit polyclonal anti-p-IRE1α (p Ser724)	Novus Biologicals	Cat#NB100-2323	Lot# AF-3
Mouse monoclonal anti-β-actin (AC-15)	Abcam	Cat#6276	Lot# GRC3207325-9
Rabbit polyclonal anti-6XHis	Abcam	Cat#ab9108	Lot# GR3246563-1
Mouse monoclonal turboGFP antibody, clone OTI2H8	Origene	Cat#TA150041	Lot#W004
Normal Rabbit IgG	Cell Signaling Technology	Cat#2729	Lot#8
Horse anti-mouse IgG (HRP-linked)	Cell Signaling Technology	Cat#7076	Lot# 31
Goat anti-rabbit IgG (HRP-linked)	Cell Signaling Technology	Cat#7074	Lot# 28
Guinea pig polyclonal anti-Insulin	Dako	Cat#A0564	Lot# 10088287
Mouse monoclonal anti-glucagon (K79bB10)	Sigma-Aldrich	Cat#G2654	
Monoclonal Anti-Ceramide antibody produced in mouse	Sigma-Aldrich	Cat#C8104	Lot# SLCC3937
Rat monoclonal anti-somatostatin (YC7)	Merk Millipore	Cat#MAB354	
Goat anti-guinea pig IgG, Alexa Fluor 488	Thermo Fisher Scientific	Cat#A11073	Lot# 1737010
Goat anti-guinea pig IgG, Alexa Fluor 568	Thermo Fisher Scientific	Cat#A11075	Lot# 1692965
Goat anti-mouse IgG, Alexa Fluor 488	Thermo Fisher Scientific	Cat#A28175	Lot# 1611153
Goat anti-Mouse IgM (Heavy chain) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	Thermo Fisher Scientific	Cat#A21042	Lot# 2079371
Goat anti-rat IgG, Alexa Fluor 647	Thermo Fisher Scientific	Cat#A21247	
Goat anti-rabbit IgG, Alexa Fluor 488	Thermo Fisher Scientific	Cat#A32731	Lot# 1622775
Bacterial and Virus Strains			
FIT2 MISSION shRNA lentiviral	Sigma-Aldrich	Cat#SHCLNV-	
transduction particles		NM_173397 (TRCN000012538 0)	
MISSION pLKO.1-puro non-target shRNA control transduction particles	Sigma-Aldrich	Cat#SHC016V	
Chemicals, Peptides, and Recombinant	Proteins		
BODIPY 493/503	Thermo Fisher Scientific	Cat#D3922	

Fura-2, AM	Thermo Fisher Scientific	Cat#F1225	
DAPI	Thermo Fisher Scientific	Cat#D1306	
Propidium iodide	Thermo Fisher Scientific	Cat#P1304MP	
Palmitic acid	Sigma-Aldrich	Cat#57-10-3	
Click-IT <sup>™</sup> Palmitic Acid, Azide (15- Azidopentadecanoic Acid)	Thermo Fisher	Cat#C10265	
Biotin Alkyne (PEG4 carboxamide- Propargyl Biotin)	Thermo Fisher	Cat#B10185	
Oleic acid	Sigma-Aldrich	Cat#112-80-1	
Stearic acid	Sigma-Aldrich	Cat#57-11-4	
Palmitoleic acid	Sigma-Aldrich	Cat#P9417	
Sodium hydroxide	Sigma-Aldrich	Cat#1310-73-2	
D-(+)-Glucose	Sigma-Aldrich	Cat#50-99-7	
Humalog U-100 insulin	Eli Lilly	Cat#HP8799	
MG-132	Cell Signaling	Cat#2194	
	Technology		
2-Bromopalmitic acid	Sigma-Aldrich	Cat#21604	
Eeyarestatin	Sigma-Aldrich	Cat#E1286	
Cerulenin	Sigma-Aldrich	Cat#C2389	
Critical Commercial Assays		·	
RNAscope 2.5 HD detection kit (red)	Advanced Cell Diagnostics	Cat#322360	
Pierce BCA protein assay kit	Thermo Fisher Scientific	Cat#23225	
Lipofectamine 2000 transfection reagent	Thermo Fisher Scientific	Cat#11668019	
Fast SYBR green master mix	Thermo Fisher Scientific	Cat#4385617	
Pierce™ Classic IP Kit	Thermo Fisher Scientific	Cat#26146	
Pierce® IP Lysis Buffer	Thermo Fisher Scientific	Cat# 87788	
RIPA buffer	Sigma-Aldrich	Cat#R0278	
Protease inhibitor cocktail	Sigma-Aldrich	Cat#P8340	
SignalFire ECL reagent	Cell Signaling Technology	Cat#6883	
ADP/ATP ratio bioluminescence assay kit	BioVision	Cat#255-200	
NucleoSpin RNA XS	Macherey-Nagel	Cat#740902	
NucleoSpin RNA	Macherey-Nagel	Cat#740955	
Mouse Insulin ELISA	Mercodia	Cat#10-1247-01	
Ultrasensitive mouse Insulin ELISA	Mercodia	Cat#10-1249-01	
Apo-ONE homogeneous caspase-3/7 assav	Promega	Cat#G7790	
CAPTUREome™ S-Palmitoylated Protein Kit	Badrilla	Cat#K010-311	
Deposited Data			
RNAseq Data	GEO	GEO: GSE133939	
Experimental Models: Cell Lines			
Min6 cells	Dr. Jun-ichi Miyazaki	(1)	

Min6 cells stably expressing control shRNA	This study	N/A	
Min6 cells stably expressing FIT2 shRNA	This study	N/A	
Human: HEK 293T/17	ATCC	Cat#CRL-11268	
Experimental Models: Organisms/Strain	S	L	
Mouse: C57BL/6J	The Jackson	Cat#000664	
	Laboratory		
Mouse: FIT2fl/fl	Dr. David L. Silver	(8)	
Mouse: B6.Cg-1g (Ins2-cre) 25Mgn/J	Laboratory	Cat#003573	
Mouse: 129S1/SvImJ	The Jackson Laboratory	Cat#002448	
Mouse: B6.Cg-Tg (Ins2-cre) 25Mgn/J:129S1/SvImJ	This study	N/A	
Mouse: C57BL/6J:129S1/SvImJ	This study	N/A	
Mouse: B6.Cg-Tg(Ins2- cre)25Mgn/J:FIT2fl/fl	This study	N/A	
Mouse: B6.BKS (D)-Lepr <sup>db</sup> /J	The Jackson Laboratory	Cat#000697	
Oligonucleotides			
ON-TARGETplus March6 siRNA SmartPool	Horizon Discovery	Cat# L-055065- 01-0020	
ON-TARGETplus Amfr siRNA SmartPool	Horizon Discovery	Cat#L-048676-01- 0020	
See Supplemental Table 2 for primer sequences	This study	N/A	
Recombinant DNA			
pcDNA3.1 mammalian expression vector	Thermo Fisher Scientific	Cat#V79020	
pcDNA3.1-FIT2	Dr. David L. Silver	(9)	
pcDNA3.1-FIT2/V5-His	Dr. David L. Silver	(9)	
pcDNA3.1-FIT2(C7A)/V5-His	Bio Basic Inc.	N/A	
pcDNA3.1-FIT2(C70A)/V5-His	Bio Basic Inc.	N/A	
pcDNA3.1-FIT2(C140A)/V5-His	Bio Basic Inc.	N/A	
pcDNA3.1-FIT2(C251A)/V5-His	Bio Basic Inc.	N/A	
pcDNA3.1-FIT2(C7/70/140/251A)/V5-His	Bio Basic Inc.	N/A	
March6 (BC059190) Mouse Tagged ORF Clone	Origene	CAT#MG207831	
Software and Algorithms			
GraphPad Prism 7	GraphPad	https://www.graph	
Image Lab 5.0	Bio-Rad	https://www.bio-	
		rad.com/en-	
		sg/product/image- lab-software	
Leica LAS X software	Leica	https://www.leica-	
		microsystems.co m/products/micro	
NIS-Elements software	Nikon	scope-software	
		scope.healthcare.	
		nikon.com/produc	
		ts/software	
ImageJ	N/A	nttps://imagej.net/ Welcome	

Other			
Chow diet	Altromin	Cat#1324	
Western diet	Research Diets	Cat#D12079B	

393

#### 394 SUPPLEMENTARY INFORMATION REFERENCES

395

Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, et al.
 Establishment of a pancreatic beta cell line that retains glucose-inducible insulin
 secretion: special reference to expression of glucose transporter isoforms.
 Endocrinology. 1990;127(1):126-32.

2. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR:
ultrafast universal RNA-seq aligner. Bioinformatics (Oxford, England). 2013;29(1):1521.

403 3. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data 404 with or without a reference genome. BMC Bioinformatics. 2011;12(1):323.

- 405 4. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L.
  406 Differential analysis of gene regulation at transcript resolution with RNA-seq. Nature
  407 biotechnology. 2013;31(1):46-53.
- 5. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al.
  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts
  and isoform switching during cell differentiation. Nature biotechnology.
  2010;28(5):511-5.
- 412 6. Hiriart M, Matteson DR. Na channels and two types of Ca channels in rat 413 pancreatic B cells identified with the reverse hemolytic plaque assay. J Gen Physiol. 414 1988;91(5):617-39.
- Kadereit B, Kumar P, Wang WJ, Miranda D, Snapp EL, Severina N, et al.
  Evolutionarily conserved gene family important for fat storage. Proceedings of the
  National Academy of Sciences of the United States of America. 2008;105(1):94-9.

8. Miranda DA, Kim JH, Nguyen LN, Cheng W, Tan BC, Goh VJ, et al. Fat
Storage-inducing Transmembrane Protein 2 Is Required for Normal Fat Storage in
Adipose Tissue. The Journal of biological chemistry. 2014;289(14):9560-72.

- 9. Gross DA, Zhan C, Silver DL. Direct binding of triglyceride to fat storageinducing transmembrane proteins 1 and 2 is important for lipid droplet formation.
  Proceedings of the National Academy of Sciences of the United States of America.
  2011;108(49):19581-6.
- 425
- 426

## Data Table S1. Oligonucleotides

Name	Forward primer (5 <sup>-3</sup> )	Reverse primer $(5' - 3')$
qPCR		
Fit2	CACGACTTGACCCAGAAAGTG	GGAGGAAGTCCTGGAGAGAAA
Ins2	CCATCAGCAAGCAGGAAGCCTATC	CCCCACACACCAGGTAGAGAGCC
MafA	GAGGTCATCCGACTGAAAC	CACTTCTCGCTCTCCAGA
Pdx-1	GAAATCCACCAAAGCTCAC	AAGAATTCCTTCTCCAGCTC
NeuroD1	AACAACAGGAAGTGGAAAC	TTTCTTGTCTGCCTCGTG
$\beta$ -actin	GACAGGATGCAGAAGGAGAT	TTGCTGATCCACATCTGCTG
Genotyping		
Cre5	GCAAGTTGAATAACCGGAAATGGTT	AGGGTGTTATAAGCAATCCCCAGAA
FL146	CCCATGTTAGTAGAAGCAAGCGTGA	ACAAGGAAAGCCTCGTTAAAACCAA